Loading clinical trials...
Loading clinical trials...
Showing 1-5 of 5 trials
NCT07093307
A cluster pilot RCT to evaluate the effectiveness of the docudrama compared to a control group (usual engagement with blood services) on repeat blood donation attempts among first-time blood donors. Secondary outcomes will be blood donor retention, attitudes, subjective norms, perceived behavioral control and intention as potential mediators of blood donation behavior among first-time blood donors. The cluster pilot RCT will have two arms: 1) docudrama and 2) control. Randomization will stratify by the type of site: mobile versus fixed. Each participant in the docudrama arm will receive the intervention one time immediately after blood donation. Participants in both the docudrama arm and control arm will receive standard blood donor communications and will be followed for six months. Actualized blood donation is possible every four months using NBSG guidelines; however, blood donation sessions may not occur at the blood donation sites until six months. Return blood donation attempts will be evaluated using the Southern Zonal Blood Center (SZBC) records (primary outcome) and participant self-report (secondary outcome) at six months. Secondary measures will be evaluated at baseline and six months from enrollment. The duration of the study will be 11 months, allowing for five months to achieve enrollment goals and six months of follow-up for the last individual enrolled.
NCT06809010
"Etablissement Français du Sang" (EFS) prepares labile blood products from blood donations that are separated by type (red blood cells, plasma and platelets). The "Centre de Transfusion Sanguine des Armées" (CTSA) produces an innovative labile blood product, LTO-WB, corresponding to group O leukocyte-free whole blood. The objective of the PEDESTAL EFS study is to compare the inflammatory and biological characteristics of blood products prepared by the EFS vs. the labile blood product prepared by the CTSA.
NCT00552214
The purpose of this study is to validate the performance characteristics of an assay that tests for HIV-1, HCV and HBV on an automated blood bank instrument for registration submission.
NCT01555060
The purpose of this study is to investigate the effect of daily iron supplements after blood donation on time to recovery of hemoglobin and iron stores. The study will also determine whether the effect of iron supplements on time to recovery is different in men and women, in older vs. younger donors (\<60 years old vs. at least 60 years old) and in donors with replete vs. diminished pre-donation iron stores.
NCT01570439
Aim: To identify HLA-A1101-restricted peptide epitopes derived from novel Oncoantigens (URLC10, KIF20A, and CDCA1) applicable for Cancer Vaccine in Singapore. Methods: The panel of candidate peptides are synthesized and tested for their ability to induce peptide-specific CTL responses, in order to screen the peptide epitopes applicable for the cancer vaccination. Briefly, peripheral blood lymphocytes (PBLs) derived from HLA-A1101(+) healthy donors are taken and cultured in the presence of the each candidate peptide with recombinant IL-2 for 2 weeks, and then, re-stimulated with dendritic cell pulsed with the peptide following another 2 week culture. Thereafter, CD8(+) T lymphocytes were negatively selected with CD4-magnetic beads from cultured lymphocytes and tested for their peptide specificity employing enzyme-linked immunospot (ELISPOT) assay. These conditions are completely performed in in-vitro system. Importance in medicine: If one could identify the peptide epitopes from novel Oncoantigens, it is applicable for clinical trials of cancer vaccination. Benefits \& Risks : There is no risk except for the matter of venipuncture in each individuals. The ideal target molecules for cancer vaccination are thought to be selectively expressed in tumor cells, but not in the normal cells, with high frequent and homogenous expression within tumor. We have proved that novel Oncoantigens, URLC10, KIF20A and CDCA1, have these characters as ideal target molecules for the cancer vaccination and are highly expressed in a variety of tumor type such as gastric, lung, and pancreas cancer. Since HLA-A1101 haplotype is most frequent in Singaporean, it is essential to indentify the HLA-A1101-restriced peptides derived from these Oncoantigens to develop cancer vaccination.